RMBS Stock Analysis: Rambus | NASDAQ
Semiconductors | NASDAQ, USA | Market Cap: 10.164m USD | 12M Return: 29.5% | US7509171069 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 224M
EPS Trend: -23.3%
Qual. Beats: 1
Rev. Trend: 98.4%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Rambus Inc. (NASDAQ: RMBS) is a U.S.-headquartered semiconductor company founded in 1990 and based in San Jose, California, operating within the Information Technology sector. The company generates revenue from two primary lines: the sale of memory interface chips (most notably DDR5 and DDR4 components such as registering clock drivers, data buffers, and power management ICs) and the licensing of silicon intellectual property covering high-speed interface and security solutions. It also monetizes a historical portfolio of patents covering memory architecture, high-speed serial links, and security technology.
Rambus sells to memory module manufacturers, OEMs, hyperscalers, and chip makers, using both a direct sales force and third-party distributors across the United States, South Korea, Singapore, and other international markets. Within the broader semiconductor industry, Rambus occupies a niche as a fabless supplier of interface and security silicon IP rather than a competing manufacturer of memory or logic devices, a business model that allows it to capture royalty and per-chip licensing revenue tied to the adoption of advanced memory standards like DDR5 in data center, AI, and automotive applications.
- DDR5 memory interface chip revenue ramps on hyperscaler demand
- Silicon IP licensing expands with AI data center adoption
- Patent royalty stream pressured by memory maker renegotiations
| Net Income: 239.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.19 > 0.02 and ΔFCF/TA 0.72 > 1.0 |
| NWC/Revenue: 129.0% < 20% (prev 110.2%; Δ 18.80% < -1%) |
| CFO/TA 0.21 > 3% & CFO 332.7m > Net Income 239.7m |
| Net Debt (-803.1m) to EBITDA (331.4m): -2.42 < 3 |
| Current Ratio: 9.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (109.9m) vs 12m ago 1.12% < -2% |
| Gross Margin: 78.27% > 18% (prev 76.02%; Δ 2.25% > 0.5%) |
| Asset Turnover: 49.11% > 50% (prev 43.98%; Δ 5.13% > 0%) |
| Interest Coverage Ratio: 258.9 > 6 (EBIT TTM 309.4m / Interest Expense TTM 1.20m) |
| A: 0.61 (Total Current Assets 1.09b - Total Current Liabilities 111.5m) / Total Assets 1.61b |
| B: 0.13 (Retained Earnings 204.3m / Total Assets 1.61b) |
| C: 0.20 (EBIT TTM 309.4m / Avg Total Assets 1.54b) |
| D: 10.07 (Book Value of Equity 1.47b / Total Liabilities 145.7m) |
| Altman-Z'' = 16.31 = AAA |
| DSRI: 1.07 (Receivables 166.9m/133.1m, Revenue 756.3m/645.5m) |
| GMI: 0.97 (GM 76.02% / 78.27%) |
| AQI: 0.64 (AQ_t 0.25 / AQ_t-1 0.38) |
| SGI: 1.17 (Revenue 756.3m / 645.5m) |
| TATA: -0.06 (NI 239.7m - CFO 332.7m) / TA 1.61b) |
| Beneish M = -3.09 (Cap -4..+1) = AA |
As of August 23, 2026, the stock is trading at USD 91.24 with a total of 1,041,818 shares traded. Over the past week, the price has changed by -9.53%, over one month by -13.75%, over three months by -35.66% and over the past year by +29.53%.
Current recommended Stop Loss: 83.00 (which is 9% or 1.2 ATR below the current price).
Rambus has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy RMBS.
- StrongBuy: 7
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 147.5 | 61.7% |
P/E Trailing = 42.9862
P/E Forward = 24.1546
P/S = 13.0283
P/B = 6.9344
P/EG = 3.8007
Revenue TTM = 756.3m USD
EBIT TTM = 309.4m USD
EBITDA TTM = 331.4m USD
Long Term Debt = 15.8m USD (estimated: total debt 21.8m - short term 6.04m)
Short Term Debt = 6.04m USD (from shortTermDebt, last quarter)
Debt = 21.8m USD (from shortLongTermDebtTotal, last quarter) (leases 21.8m already included)
Net Debt = -803.1m USD (calculated: Debt 21.8m - CCE 824.9m)
Enterprise Value = 9.36b USD (10.2b + Debt 21.8m - CCE 824.9m)
Interest Coverage Ratio = 258.9 (Ebit TTM 309.4m / Interest Expense TTM 1.20m)
EV/FCF = 31.25x (Enterprise Value 9.36b / FCF TTM 299.5m)
FCF Yield = 3.20% (FCF TTM 299.5m / Enterprise Value 9.36b)
FCF Margin = 39.60% (FCF TTM 299.5m / Revenue TTM 756.3m)
Net Margin = 31.69% (Net Income TTM 239.7m / Revenue TTM 756.3m)
Gross Margin = 78.27% ((Revenue TTM 756.3m - Cost of Revenue TTM 164.4m) / Revenue TTM)
Gross Margin QoQ = 79.76% (prev 79.73%)
Tobins Q-Ratio = 5.81 (Enterprise Value 9.36b / Total Assets 1.61b)
Interest Expense / Debt = 5.48% (Interest Expense 1.20m / Debt 21.8m)
Taxrate = 18.65% (54.9m / 294.6m)
NOPAT = 251.7m (EBIT 309.4m * (1 - 18.65%))
Current Ratio = 9.75 (Total Current Assets 1.09b / Total Current Liabilities 111.5m)
Debt / Equity = 0.01 (Debt 21.8m / totalStockholderEquity, last quarter 1.47b)
Debt / EBITDA = -2.42 (Net Debt -803.1m / EBITDA 331.4m)
Debt / FCF = -2.68 (Net Debt -803.1m / FCF TTM 299.5m)
Total Stockholder Equity = 1.38b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.56% (Net Income 239.7m / Total Assets 1.61b)
RoE = 17.39% (Net Income TTM 239.7m / Total Stockholder Equity 1.38b)
RoCE = 22.20% (EBIT 309.4m / Capital Employed (Equity 1.38b + L.T.Debt 15.8m))
RoIC = 17.14% (NOPAT 251.7m / Invested Capital 1.47b)
WACC = 16.44% (E(10.2b)/V(10.2b) * Re(16.47%) + D(21.8m)/V(10.2b) * Rd(5.48%) * (1-Tc(0.19)))
Discount Rate = 16.47% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 29.03 | Cagr: -0.07%
[DCF] Terminal Value 56.01% ; FCFF base≈284.6m ; Y1≈324.2m ; Y5≈469.8m
[DCF] Fair Price = 33.96 (EV 2.88b - Net Debt -803.1m = Equity 3.68b / Shares 108.5m; r=16.44% [WACC]; 5y FCF grow 14.29% → 2.50% )
EPS Correlation: -23.31 | EPS CAGR: -3.51% | SUE: 1.04 | # QB: 1
Revenue Correlation: 98.36 | Revenue CAGR: 23.17% | SUE: 1.06 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.79 | Chg30d=+1.13% | Revisions=+29% | Analysts=8
EPS current Year (2026-12-31): EPS=3.03 | Chg30d=+2.75% | Revisions=+44% | GrowthEPS=+23.5% | GrowthRev=+16.9%
EPS next Year (2027-12-31): EPS=3.70 | Chg30d=+0.76% | Revisions=+38% | GrowthEPS=+21.9% | GrowthRev=+19.7%
[Analyst] Revisions Ratio: +50% (up=12, down=3)